What is Redesign Science?
Redesign Science leverages its proprietary NUVO technology platform, which merges physics simulation with generative artificial intelligence. This innovative approach enables the company to simulate biomolecular systems at an atomic level. Their primary focus is on developing first-in-class small molecule Targeted Protein Interaction Modulators (TPIMs). By targeting the structural protein interactome, Redesign Science aims to achieve enhanced control over cellular biology, paving the way for novel therapeutic interventions. The company's integrated science and technology strategy positions it at the forefront of drug discovery, addressing complex biological challenges with precision and advanced computational power.
How much funding has Redesign Science raised?
Redesign Science has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2021): $15M with participation from Preface Ventures, Notation Capital, 5Y Capital, Acequia Capital, Refactor Capital, HawkTail, Third Kind Venture Capital, and Collaborative Fund
Key Investors in Redesign Science
Preface Ventures
Preface Ventures is an early-stage investment firm that focuses on enterprise infrastructure and software solutions, providing significant capital to founders and often acting as the first investor in a startup's journey.
Notation Capital
Notation Capital is a first-check venture fund based in Brooklyn, NY, that invests in very early-stage technical teams, primarily in New York, offering capital and support for go-to-market strategies.
5Y Capital
五源资本 (formerly 晨兴资本) is an investment firm that identifies and nurtures exceptional entrepreneurs, focusing on contributing to societal progress through innovative businesses across various sectors.
What's next for Redesign Science?
With the recent major strategic investment, Redesign Science is poised to accelerate its internal therapeutics pipeline and further refine its NUVO platform. The substantial backing suggests a strong validation of their approach to drug discovery, particularly in the challenging area of protein-protein interactions. This capital will likely be directed towards expanding research and development efforts, potentially scaling their computational capabilities, and advancing their lead drug candidates through preclinical and clinical stages. The company's focus on small molecule TPIMs indicates a strategic move towards developing highly specific and potentially more effective treatments for a range of diseases.
See full Redesign Science company page
